3.An iron regulator hepcidin is affected by EPO.
Xue-Feng SUN ; Dao-Bin ZHOU ; Yong-Qiang ZHAO
Journal of Experimental Hematology 2006;14(4):778-782
To investigate the effect of EPO on hepcidin mRNA expression in normal mice, acute inflammatory mice and ACD mice, the acute phase model and ACD model of mouse was produced by subcutaneous injection of turpentine oil. Hepatic hepcidin mRNA expression levels of normal mice, acute inflammatory mice and ACD mice were detected by semi-quantitative retro-transcriptase polymerase chain reaction (RT-PCR) after intra-peritoneal injection of EPO. The results showed that prolonged chronic inflammation did not significantly increase mouse hepatic hepcidin mRNA expression, but a single injection of turpentine oil increased mouse hepatic hepcidin mRNA expression transiently. Intra-peritoneal injection of EPO down-regulated hepatic hepcidin mRNA expression in normal mice, ACD mice and acute inflammatory mice. Hb levels had a negative correlation with hepatic hepcidin mRNA expression levels in ACD mice treated with EPO. It is concluded that the ACD model can be produced by repeated subcutaneous injection of turpentine oil. Hepatic hepcidin mRNA expression increased during the early period of ACD process and then fall to normal level. EPO down-regulate hepcidin mRNA expression under the normal, acute inflammation and chronic inflammation conditions.
Anemia
;
chemically induced
;
metabolism
;
Animals
;
Antimicrobial Cationic Peptides
;
biosynthesis
;
genetics
;
Erythropoietin
;
pharmacology
;
Hepcidins
;
Inflammation
;
chemically induced
;
metabolism
;
Iron
;
metabolism
;
Liver
;
metabolism
;
Male
;
Mice
;
Mice, Inbred C57BL
;
RNA, Messenger
;
biosynthesis
;
genetics
;
Random Allocation
4.Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy.
Jow Jyh HWANG ; Ching Chu LO ; Chien Hung LIN ; Hsu Sheng CHENG ; I Wen HUNG ; Wan Ju TSAI ; Chien Hui HUNG
Gut and Liver 2015;9(2):214-223
BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect against anemia during the early stages of HCV combination treatments but have also been associated with larger decreases in platelet counts. We aimed to identify the association between specific ITPA gene polymorphisms and hematological abnormalities in patients undergoing HCV combination therapy. METHODS: In this retrospective study, 175 patients treated with HCV combination therapy were enrolled at St. Martin De Porres Hospital in Taiwan between 2006 and 2012. Two single nucleotide polymorphisms (SNP) within or adjacent to the ITPA gene (rs1127354, rs6051702) were genotyped. We investigated the effect of ITPA gene variants on hematological abnormalities during the therapy. RESULTS: The ITPA rs1127354 minor variants were significantly associated with protection against anemia at week 4 (p=1.86 x 10(-6)) and with more severe decreases in platelet counts during HCV combination therapy. SNP rs6051702 was not associated with the hemoglobin decline to >3 g/dL at week 4 in our study (p=0.055). CONCLUSIONS: The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy.
Adult
;
Aged
;
Anemia/chemically induced/genetics
;
Antiviral Agents/*adverse effects
;
Cross-Sectional Studies
;
Drug Therapy, Combination/adverse effects
;
Female
;
Hematologic Diseases/*chemically induced/genetics
;
Hepacivirus
;
Hepatitis C/*drug therapy
;
Humans
;
Interferon-alpha/adverse effects
;
Male
;
Middle Aged
;
*Polymorphism, Single Nucleotide
;
Pyrophosphatases/*genetics
;
Retrospective Studies
;
Ribavirin/adverse effects
;
Taiwan
;
Thrombocytopenia/chemically induced/genetics
5.Association between IPTA Gene Polymorphisms and Hematological Abnormalities in Hepatitis C Virus-Infected Patients Receiving Combination Therapy.
Jow Jyh HWANG ; Ching Chu LO ; Chien Hung LIN ; Hsu Sheng CHENG ; I Wen HUNG ; Wan Ju TSAI ; Chien Hui HUNG
Gut and Liver 2015;9(2):214-223
BACKGROUND/AIMS: Hematological abnormalities during hepatitis C virus (HCV) combination therapy with pegylated interferon alpha and ribavirin often necessitate dose reduction. Variants of the ITPA gene have been reported to protect against anemia during the early stages of HCV combination treatments but have also been associated with larger decreases in platelet counts. We aimed to identify the association between specific ITPA gene polymorphisms and hematological abnormalities in patients undergoing HCV combination therapy. METHODS: In this retrospective study, 175 patients treated with HCV combination therapy were enrolled at St. Martin De Porres Hospital in Taiwan between 2006 and 2012. Two single nucleotide polymorphisms (SNP) within or adjacent to the ITPA gene (rs1127354, rs6051702) were genotyped. We investigated the effect of ITPA gene variants on hematological abnormalities during the therapy. RESULTS: The ITPA rs1127354 minor variants were significantly associated with protection against anemia at week 4 (p=1.86 x 10(-6)) and with more severe decreases in platelet counts during HCV combination therapy. SNP rs6051702 was not associated with the hemoglobin decline to >3 g/dL at week 4 in our study (p=0.055). CONCLUSIONS: The ITPA SNP rs1127354 is a useful predictor of ribavirin-induced anemia in Taiwanese patients and may be related to more severe decreases in platelet counts during the early stage of HCV combination therapy.
Adult
;
Aged
;
Anemia/chemically induced/genetics
;
Antiviral Agents/*adverse effects
;
Cross-Sectional Studies
;
Drug Therapy, Combination/adverse effects
;
Female
;
Hematologic Diseases/*chemically induced/genetics
;
Hepacivirus
;
Hepatitis C/*drug therapy
;
Humans
;
Interferon-alpha/adverse effects
;
Male
;
Middle Aged
;
*Polymorphism, Single Nucleotide
;
Pyrophosphatases/*genetics
;
Retrospective Studies
;
Ribavirin/adverse effects
;
Taiwan
;
Thrombocytopenia/chemically induced/genetics
6.A novel approach based on metabolomics coupled with network pharmacology to explain the effect mechanisms of Danggui Buxue Tang in anaemia.
Yong-Li HUA ; Qi MA ; Zi-Wen YUAN ; Xiao-Song ZHANG ; Wan-Ling YAO ; Peng JI ; Jun-Jie HU ; Yan-Ming WEI
Chinese Journal of Natural Medicines (English Ed.) 2019;17(4):275-290
Danggui Buxue Tang (DBT) is a famous Chinese medicinal decoction. Mechanism of DBT action is wide ranging and unclear. Exploring new ways of treatment with DBT is useful. Sprague-Dawley(SD) rats were randomly divided into 3 groups including control (NC, Saline), the DBT (at a dose of 8.10 g), and blood deficiency(BD) (Cyclophosphamide (APH)-andCyclophosphamide(CTX)-induced anaemia). A metabolomics approach using Liquid Chromatography-Quadrupole-Time-of-Flight/Mass Spectrometry (LC/Q-TOFMS) was developed to perform the plasma metabolic profiling analysis and differential metaboliteswerescreened according to the multivariate statistical analysiscomparing the NC and BD groups, andthe hub metabolites were outliers with high scores of the centrality indices. Anaemia disease-related protein target and compound of DBT databases were constructed. The TCMSP, ChemMapper and STITCH databases were used to predict the protein targets of DBT. Using the Cytoscape 3.2.1 to establish a phytochemical component-target protein interaction network and establish a component, protein and hub metabolite protein-protein interaction (PPI) network and merging the three PPI networks basing on BisoGenet. The gene enrichment analysis was used to analyse the relationship between proteins based on the relevant genetic similarity by ClueGO. The results shown DBT effectively treated anaemia in vivo. 11 metabolic pathways are involved in the therapeutic effect of DBT in vivo; S-adenosyl-l-methionine, glycine, l-cysteine, arachidonic acid (AA) and phosphatidylcholine(PC) were screened as hub metabolites in APH-and CTX-induced anaemia. A total of 288 targets were identified as major candidates for anaemia progression. The gene-set enrichment analysis revealed that the targets are involved in iron ion binding, haemopoiesis, reactive oxygen species production, inflammation and apoptosis. The results also showed that these targets were associated with iron ion binding, haemopoiesis, ROS production, apoptosis, inflammation and related signalling pathways. DBT can promote iron ion binding and haemopoiesis activities, restrain inflammation, production of reactive oxygen, block apoptosis, and contribute significantly to the DBT treat anaemia.
Anemia
;
blood
;
chemically induced
;
drug therapy
;
metabolism
;
Animals
;
Chromatography, Liquid
;
Cyclophosphamide
;
toxicity
;
Disease Models, Animal
;
Drugs, Chinese Herbal
;
chemistry
;
pharmacology
;
therapeutic use
;
Metabolic Networks and Pathways
;
drug effects
;
genetics
;
Metabolome
;
drug effects
;
Metabolomics
;
Rats, Sprague-Dawley
;
Signal Transduction
;
drug effects
;
Tandem Mass Spectrometry